LOS ANGELES
,

Oct. 17, 2024
/PRNewswire/ —
Glancy Prongay & Murray LLP announces that investors holding Allarity Therapeutics, Inc. securities (ALLR) have the opportunity to take the lead in a securities fraud class action lawsuit against the company.

Class Period:
May 17, 2022 – July 19, 2024

Lead Plaintiff Deadline:
November 12, 2024

If you wish to take the helm as the lead plaintiff in the Allarity lawsuit, you can provide your contact information at www.glancylaw.com/cases/Allarity-Therapeutics-Inc/. For more details on your rights, feel free to reach out to Charles H. Linehan of GPM at 310-201-9150 or Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com.

The complaint unveiled a series of allegations stating that, during the Class Period, Allarity failed to disclose key information to investors including overstatements regarding the Dovitinib NDA’s regulatory prospects and engagement in improper conduct by the company and former officers. This misconduct placed the company in the crosshairs of regulatory and enforcement scrutiny, leading to substantial legal and reputational risks. Additionally, the company downplayed the likelihood of facing enforcement actions following investigations, painting a misleading picture of its business and operations.

Stay tuned for further updates by following us on LinkedIn, Twitter, or Facebook.

To be part of the class action, no immediate action is required; you can choose to retain your preferred legal representation or stay as an absent member. For inquiries or more information, please contact Charles Linehan, Esquire, of GPM at 310-201-9150, Toll-Free at 888-773-9224, via email at shareholders@glancylaw.com, or visit www.glancylaw.com. When inquiring via email, kindly include your contact details.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts 

Glancy Prongay & Murray LLP,
Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

View original content:
https://www.prnewswire.com/news-releases/allr-investors-have-opportunity-to-lead-allarity-therapeutics-inc-securities-fraud-lawsuit-302271216.html

SOURCE Glancy Prongay & Murray LLP